

- 227 Lok AS, Lai CL. Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology. *J Hepatol* 1990; 10: 29–34.
- 228 Hadziyannis SJ, Papatheodoridis GV. Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. *Semin Liver Dis* 2006; 26: 130–41.
- 229 Harris RA, Chen G, Lin WY *et al.* Spontaneous clearance of high-titer serum HBV DNA and risk of hepatocellular carcinoma in a Chinese population. *Cancer Causes Control* 2003; 14: 995–1000.
- 230 Yang HI, Lu SN, Liaw YF *et al.* Hepatitis B e antigen and the risk of hepatocellular carcinoma. *N Engl J Med* 2002; 347: 168–74.
- 231 Yu MW, Yeh SH, Chen PJ *et al.* Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. *J Natl Cancer Inst* 2005; 97: 265–72.
- 232 de Jongh FE, Janssen HL, de Man RA *et al.* Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. *Gastroenterology* 1992; 103: 1630–5.
- 233 Moucari R, Korevaar A, Lada O *et al.* High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. *J Hepatol* 2009; 50: 1084–92.
- 234 Bortolotti F, Guido M, Bartolacci S *et al.* Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study. *Hepatology* 2006; 43: 556–62.
- 235 Chen QY, Liu YH, Li JH *et al.* DNA-dependent activator of interferon-regulatory factors inhibits hepatitis B virus replication. *World J Gastroenterol* 2012; 18: 2850–8.
- 236 de Franchis R, Meucci G, Vecchi M *et al.* The natural history of asymptomatic hepatitis B surface antigen carriers. *Ann Intern Med* 1993; 118: 191–4.
- 237 Hoofnagle JH, Dusheiko GM, Seeff LB *et al.* Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. *Ann Intern Med* 1981; 94: 744–8.
- 238 Hsu YS, Chien RN, Yeh CT *et al.* Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. *Hepatology* 2002; 35: 1522–7.
- 239 Tai DI, Lin SM, Sheen IS *et al.* Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time. *Hepatology* 2009; 49: 1859–67.
- 240 Martinot-Peignoux M, Boyer N, Colombat M *et al.* Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. *J Hepatol* 2002; 36: 543–6.
- 241 Davis GL, Hoofnagle JH, Waggoner JG. Spontaneous reactivation of chronic hepatitis B virus infection. *Gastroenterology* 1984; 86: 230–5.
- 242 Brunetto MR, Giarin M, Oliveri F *et al.* “e” antigen defective hepatitis B virus and course of chronic infection. *J Hepatol* 1991; 13 (Suppl 4): S82–6.
- 243 Brunetto MR, Oliveri F, Coco B *et al.* Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. *J Hepatol* 2002; 36: 263–70.
- 244 Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. *Hepatology* 2001; 34: 617–24.
- 245 Brunetto MR, Giarin MM, Oliveri F *et al.* Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. *Proc Natl Acad Sci U S A* 1991; 88: 4186–90.
- 246 Hosaka T, Suzuki F, Kobayashi M *et al.* Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study. *J Gastroenterol* 2013; 48: 930–41.
- 247 Hoofnagle JH, Di Bisceglie AM, Waggoner JG *et al.* Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. *Gastroenterology* 1993; 104: 1116–21.
- 248 Perrillo R, Tamburro C, Regenstein F *et al.* Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. *Gastroenterology* 1995; 109: 908–16.
- 249 Perrillo RP, Schiff ER, Davis GL *et al.* A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. *N Engl J Med* 1990; 323: 295–301.
- 250 Liaw YF, Sung JJ, Chow WC *et al.* Lamivudine for patients with chronic hepatitis B and advanced liver disease. *N Engl J Med* 2004; 351: 1521–31.
- 251 Chang TT, Liaw YF, Wu SS *et al.* Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. *Hepatology* 2010; 52: 886–93.
- 252 Fontana RJ, Hann HW, Perrillo RP *et al.* Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. *Gastroenterology* 2002; 123: 719–27.
- 253 Villeneuve JP, Condreay LD, Willems B *et al.* Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. *Hepatology* 2000; 31: 207–10.
- 254 Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. *J Hepatol* 2000; 33: 301–7.
- 255 Shim JH, Lee HC, Kim KM *et al.* Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. *J Hepatol* 2010; 52: 176–82.
- 256 Liaw YF, Raptopoulou-Gigi M, Cheinquer H *et al.* Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. *Hepatology* 2011; 54: 91–100.
- 257 Lange CM, Bojunga J, Hofmann WP *et al.* Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. *Hepatology* 2009; 50: 2001–6.

- 258 Lin SM, Sheen IS, Chien RN *et al.* Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. *Hepatology* 1999; 29: 971–5.
- 259 Mazzella G, Saracco G, Festi D *et al.* Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial. *Am J Gastroenterol* 1999; 94: 2246–50.
- 260 Yuen MF, Hui CK, Cheng CC *et al.* Long-term follow-up of interferon alpha treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. *Hepatology* 2001; 34: 139–45.
- 261 Ikeda K, Saitoh S, Suzuki Y *et al.* Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study. *Cancer* 1998; 82: 827–35.
- 262 Krogsgaard K. The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. The Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP). Executive Team on Anti-Viral Treatment. *J Viral Hepat* 1998; 5: 389–97.
- 263 Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. International Interferon-alpha Hepatocellular Carcinoma Study Group. *Lancet* 1998; 351: 1535–9.
- 264 Tangkijvanich P, Thong-ngam D, Mahachai V *et al.* Long-term effect of interferon therapy on incidence of cirrhosis and hepatocellular carcinoma in Thai patients with chronic hepatitis B. *Southeast Asian J Trop Med Public Health* 2001; 32: 452–8.
- 265 Truong BX, Seo Y, Kato M *et al.* Long-term follow-up of Japanese patients with chronic hepatitis B treated with interferon-alpha. *Int J Mol Med* 2005; 16: 279–84.
- 266 Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. *J Hepatol* 2001; 34: 306–13.
- 267 Yang YF, Zhao W, Zhong YD *et al.* Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. *J Viral Hepat* 2009; 16: 265–71.
- 268 Miyake Y, Kobashi H, Yamamoto K. Meta-analysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. *J Gastroenterol* 2009; 44: 470–5.
- 269 Camma C, Giunta M, Andreone P *et al.* Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. *J Hepatol* 2001; 34: 593–602.
- 270 Sung JJ, Tsoi KK, Wong VW *et al.* Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. *Aliment Pharmacol Ther* 2008; 28: 1067–77.
- 271 Matsumoto A, Tanaka E, Rokuhara A *et al.* Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: a multicenter retrospective study of 2795 patients. *Hepatol Res* 2005; 32: 173–84.
- 272 Yuen MF, Seto WK, Chow DH *et al.* Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. *Antivir Ther* 2007; 12: 1295–303.
- 273 Eun JR, Lee HJ, Kim TN *et al.* Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease. *J Hepatol* 2010; 53: 118–25.
- 274 Hosaka T, Suzuki F, Kobayashi M *et al.* Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. *Hepatology* 2013; 58: 98–107.
- 275 Wong GL, Chan HL, Mak CH *et al.* Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. *Hepatology* 2013; 58: 1537–47.
- 276 Kobayashi M, Arase Y, Ikeda K *et al.* Viral genotypes and response to interferon in patients with acute prolonged hepatitis B virus infection of adulthood in Japan. *J Med Virol* 2002; 68: 522–8.
- 277 Tillmann HL, Hadem J, Leifeld L *et al.* Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. *J Viral Hepat* 2006; 13: 256–63.
- 278 Yu JW, Sun LJ, Zhao YH *et al.* The study of efficacy of lamivudine in patients with severe acute hepatitis B. *Dig Dis Sci* 2010; 55: 775–83.
- 279 Wong VW, Wong GL, Yiu KK *et al.* Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. *J Hepatol* 2011; 54: 236–42.
- 280 Kobayashi M, Arase Y, Ikeda K *et al.* Clinical features of hepatitis B virus genotype A in Japanese patients. *J Gastroenterol* 2003; 38: 656–62.
- 281 Yotsuyanagi H, Okuse C, Yasuda K *et al.* Distinct geographic distributions of hepatitis B virus genotypes in patients with acute infection in Japan. *J Med Virol* 2005; 77: 39–46.
- 282 Tamada Y, Yatsushashi H, Masaki N *et al.* Hepatitis B virus strains of subgenotype A2 with an identical sequence spreading rapidly from the capital region to all over Japan in patients with acute hepatitis B. *Gut* 2012; 61: 765–73.
- 283 McMahon MA, Jilek BL, Brennan TP *et al.* The HBV drug entecavir – effects on HIV-1 replication and resistance. *N Engl J Med* 2007; 356: 2614–21.
- 284 Sheldon JA, Corral A, Rodes B *et al.* Risk of selecting K65R in antiretroviral-naïve HIV-infected individuals with chronic hepatitis B treated with adefovir. *AIDS* 2005; 19: 2036–8.
- 285 Tsubouchi H, Oketani M, Ido A *et al.* Health and Science Research Grant from Ministry of Health, Labour and Welfare. Research on Intractable Diseases. National survey of fulminant hepatitis and late onset hepatic failure (LOHF) (2009). 2010 report by the Intractable

- Hepato-Biliary Diseases Study Group. 2011; 96-113. (In Japanese.)
- 286 Mochida T, Takigawa Y, Nakayama N *et al.* Health and Science Research Grant from Ministry of Health, Labour and Welfare. Research on Intractable Diseases. The concept of "acute liver failure" in Japan, and establishment of diagnostic criteria. Report by the Intractable Hepato-Biliary Diseases Study Group, Working Group - 1 Kanzo 2011;52:393-98. (In Japanese.)
- 287 Mochida S, Takikawa Y, Nakayama N *et al.* Diagnostic criteria of acute liver failure: a report by the Intractable Hepato-Biliary Diseases Study Group of Japan. *Hepatol Res* 2011; 41: 805-12.
- 288 Oketani M, Ido A, Uto H *et al.* Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. *Hepatol Res* 2012; 42: 627-36.
- 289 Nakao R, Yatsushashi H, Akeji M *et al.* Discrimination between acute hepatitis B and acute exacerbations of chronic hepatitis B by measurement of IgM class antibody to hepatitis B core antigen by CLIA method. *Kanzo* 2006; 47: 279-82. (In Japanese.)
- 290 Omata M, Ehata T, Yokosuka O *et al.* Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. *N Engl J Med* 1991; 324: 1699-704.
- 291 Sato S, Suzuki K, Akahane Y *et al.* Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. *Ann Intern Med* 1995; 122: 241-8.
- 292 Imamura T, Yokosuka O, Kurihara T *et al.* Distribution of hepatitis B viral genotypes and mutations in the core promoter and precore regions in acute forms of liver disease in patients from Chiba, Japan. *Gut* 2003; 52: 1630-7.
- 293 Kusakabe A, Tanaka Y, Mochida S *et al.* Case-control study for the identification of virological factors associated with fulminant hepatitis B. *Hepatol Res* 2009; 39: 648-56.
- 294 Pollicino T, Zanetti AR, Cacciola I *et al.* Pre-S2 defective hepatitis B virus infection in patients with fulminant hepatitis. *Hepatology* 1997; 26: 495-9.
- 295 Kalinina T, Riu A, Fischer L *et al.* A dominant hepatitis B virus population defective in virus secretion because of several S-gene mutations from a patient with fulminant hepatitis. *Hepatology* 2001; 34: 385-94.
- 296 Bock CT, Tillmann HL, Maschek HJ *et al.* A preS mutation isolated from a patient with chronic hepatitis B infection leads to virus retention and misassembly. *Gastroenterology* 1997; 113: 1976-82.
- 297 Degertekin B, Lok AS. Indications for therapy in hepatitis B. *Hepatology* 2009; 49: S129-37.
- 298 Miyake Y, Iwasaki Y, Takaki A *et al.* Lamivudine treatment improves the prognosis of fulminant hepatitis B. *Intern Med* 2008; 47: 1293-9.
- 299 Yu JW, Sun LJ, Yan BZ *et al.* Lamivudine treatment is associated with improved survival in fulminant hepatitis B. *Liver Int* 2011; 31: 499-506.
- 300 Fujiwara K, Mochida T, Matsui A. Health and Science Research Grant from Ministry of Health, Labour and Welfare. Research on Intractable Diseases. National survey of fulminant hepatitis and late onset hepatic failure (LOHF) (2003). 2004 report by the Intractable Hepatic Diseases Study Group. 2005; 93-107. (In Japanese.)
- 301 Cholongitas E, Papatheodoridis GV, Burroughs AK. Liver grafts from anti-hepatitis B core positive donors: a systematic review. *J Hepatol* 2010; 52: 272-9.
- 302 Saab S, Waterman B, Chi AC *et al.* Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: a systematic review. *Liver Transpl* 2010; 16: 300-7.
- 303 Kondili LA, Osman H, Mutimer D. The use of lamivudine for patients with acute hepatitis B (a series of cases). *J Viral Hepat* 2004; 11: 427-31.
- 304 Jochum C, Gieseler RK, Gawlista I *et al.* Hepatitis B-associated acute liver failure: immediate treatment with entecavir inhibits hepatitis B virus replication and potentially its sequelae. *Digestion* 2009; 80: 235-40.
- 305 Garg H, Sarin SK, Kumar M *et al.* Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. *Hepatology* 2011; 53: 774-80.
- 306 De Socio GV, Mercuri A, Di Candilo F *et al.* Entecavir to treat severe acute hepatitis B. *Scand J Infect Dis* 2009; 41: 703-4.
- 307 Yoshida M, Sekiyama K, Inoue K *et al.* Interferon and cyclosporin A in the treatment of fulminant viral hepatitis. *J Gastroenterol* 1995; 30: 67-73.
- 308 Milazzo F, Galli M, Fassio PG *et al.* Attempted treatment of fulminant viral hepatitis with human fibroblast interferon. *Infection* 1985; 13: 130-3.
- 309 Sanchez-Tapias JM, Mas A, Costa J *et al.* Recombinant alpha 2c-interferon therapy in fulminant viral hepatitis. *J Hepatol* 1987; 5: 205-10.
- 310 Oketani M, Ido A, Uto H *et al.* Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. *Hepatol Res* 2012; 42: 627-36.
- 311 Tsubouchi H, Kumada H, Kiyosawa K *et al.* Guidelines for the prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy (Revised version). Intractable Hepato-Biliary Diseases Study Group Fulminant Hepatitis Subgroup and Standardization of Treatment of Viral Hepatitis and Cirrhosis Study Group of the Ministry of Health, Labour and Welfare. 2011. (In Japanese.)
- 312 Kusumoto S, Tanaka Y, Suzuki R *et al.* Prospective nationwide observational study of hepatitis B virus (HBV) DNA monitoring and preemptive antiviral therapy for HBV

- reactivation in patients with B-cell non-Hodgkin lymphoma following rituximab containing chemotherapy: results of interim analysis. *Blood* 2012; **120**: 2641.
- 313 Mochida T. Health and Science Research Grant from Ministry of Health, Labour and Welfare. Research on Hepatitis. HBV Reactivation through immunosuppressive and/or anti-cancer therapies, elucidation and establishment of countermeasures. 2011 report by the "HBV Reactivation through Immunosuppressive and/or Anti-cancer Therapies" Research Group, 2012. (In Japanese.)
- 314 Japan College of Rheumatology. A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy. 2011. (In Japanese.)
- 315 Berger A, Preiser W, Kachel HG *et al.* HBV reactivation after kidney transplantation. *J Clin Virol* 2005; **32**: 162–5.
- 316 Hui CK, Cheung WW, Zhang HY *et al.* Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. *Gastroenterology* 2006; **131**: 59–68.
- 317 Westhoff TH, Jochimsen F, Schmittl A *et al.* Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. *Blood* 2003; **102**: 1930.
- 318 Cheng J, Li JB, Sun QL *et al.* Reactivation of hepatitis B virus after steroid treatment in rheumatic diseases. *J Rheumatol* 2011; **38**: 181–2.
- 319 Narvaez J, Rodriguez-Moreno J, Martinez-Aguila MD *et al.* Severe hepatitis linked to B virus infection after withdrawal of low dose methotrexate therapy. *J Rheumatol* 1998; **25**: 2037–8.
- 320 Hagiwara H, Kubota T, Komano Y *et al.* Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis. *Clin Exp Rheumatol* 2004; **22**: 375–6.
- 321 Ito S, Nakazono K, Murasawa A *et al.* Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. *Arthritis Rheum* 2001; **44**: 339–42.
- 322 Chen CH, Chen PJ, Chu JS *et al.* Fibrosing cholestatic hepatitis in a hepatitis B surface antigen carrier after renal transplantation. *Gastroenterology* 1994; **107**: 1514–18.
- 323 McIvor C, Morton J, Bryant A *et al.* Fatal reactivation of precore mutant hepatitis B virus associated with fibrosing cholestatic hepatitis after bone marrow transplantation. *Ann Intern Med* 1994; **121**: 274–5.
- 324 Vassilopoulos D, Calabrese LH. Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections. *Curr Opin Rheumatol* 2007; **19**: 619–25.
- 325 Yeo W, Chan PK, Ho WM *et al.* Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. *J Clin Oncol* 2004; **22**: 927–34.
- 326 Hsu C, Hsiung CA, Su IJ *et al.* A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. *Hepatology* 2008; **47**: 844–53.
- 327 Lau GK, He ML, Fong DY *et al.* Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. *Hepatology* 2002; **36**: 702–9.
- 328 Loomba R, Rowley A, Wesley R *et al.* Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. *Ann Intern Med* 2008; **148**: 519–28.
- 329 Watanabe M, Shibuya A, Takada J *et al.* Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients. *Eur J Intern Med* 2010; **21**: 333–7.
- 330 Jimenez-Perez M, Saez-Gomez AB, Mongil Poce L *et al.* Efficacy and safety of entecavir and/or tenofovir for prophylaxis and treatment of hepatitis B recurrence post-liver transplant. *Transplant Proc* 2010; **42**: 3167–8.
- 331 Tamori A, Koike T, Goto H *et al.* Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. *J Gastroenterol* 2011; **46**: 556–64.
- 332 Uemoto S, Sugiyama K, Marusawa H *et al.* Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. *Transplantation* 1998; **65**: 494–9.
- 333 Terrault N. Management of hepatitis B virus infection in liver transplant recipients: prospects and challenges. *Clin Transplant* 2000; **14** (Suppl 2): 39–43.
- 334 Markowitz JS, Martin P, Conrad AJ *et al.* Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. *Hepatology* 1998; **28**: 585–9.
- 335 Umeda M, Marusawa H, Ueda M *et al.* Beneficial effects of short-term lamivudine treatment for de novo hepatitis B virus reactivation after liver transplantation. *Am J Transplant* 2006; **6**: 2680–5.
- 336 Marcellin P, Giostra E, Martinot-Peignoux M *et al.* Redevelopment of hepatitis B surface antigen after renal transplantation. *Gastroenterology* 1991; **100**: 1432–4.
- 337 Dusheiko G, Song E, Bowyer S *et al.* Natural history of hepatitis B virus infection in renal transplant recipients—a fifteen-year follow-up. *Hepatology* 1983; **3**: 330–6.
- 338 Degos F, Lugassy C, Degott C *et al.* Hepatitis B virus and hepatitis B-related viral infection in renal transplant recipients. A prospective study of 90 patients. *Gastroenterology* 1988; **94**: 151–6.
- 339 Park SK, Yang WS, Lee YS *et al.* Outcome of renal transplantation in hepatitis B surface antigen-positive patients after introduction of lamivudine. *Nephrol Dial Transplant* 2001; **16**: 2222–8.

- 340 Lau GK, Liang R, Chiu EK *et al.* Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study. *Bone Marrow Transplant* 1997; 19: 795–9.
- 341 Dhedin N, Douvin C, Kuentz M *et al.* Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. *Transplantation* 1998; 66: 616–19.
- 342 Seth P, Alrajhi AA, Kagevi I *et al.* Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease. *Bone Marrow Transplant* 2002; 30: 189–94.
- 343 Matsue K, Aoki T, Odawara J *et al.* High risk of hepatitis B-virus reactivation after hematopoietic cell transplantation in hepatitis B core antibody-positive patients. *Eur J Haematol* 2009; 83: 357–64.
- 344 Oshima K, Sato M, Okuda S *et al.* Reverse seroconversion of hepatitis B virus after allogeneic hematopoietic stem cell transplantation in the absence of chronic graft-versus-host disease. *Hematology* 2009; 14: 73–5.
- 345 Yeo W, Chan PK, Zhong S *et al.* Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. *J Med Virol* 2000; 62: 299–307.
- 346 Yeo W, Chan TC, Leung NW *et al.* Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. *J Clin Oncol* 2009; 27: 605–11.
- 347 Hsu C, Tsou H, Lin S *et al.* Incidence of hepatitis B (HBV) reactivation in non-Hodgkins lymphoma patients with resolved HBV infection and received rituximab-containing chemotherapy. *Hepato Int* 2012; 6: 65.
- 348 Umemura T, Tanaka E, Kiyosawa K *et al.* Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. *Clin Infect Dis* 2008; 47: e52–6.
- 349 Lau GK, Yiu HH, Fong DY *et al.* Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. *Gastroenterology* 2003; 125: 1742–9.
- 350 Lok AS, Liang RH, Chiu EK *et al.* Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. *Gastroenterology* 1991; 100: 182–8.
- 351 Nakamura Y, Motokura T, Fujita A *et al.* Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987–1991. *Cancer* 1996; 78: 2210–15.
- 352 Yeo W, Zee B, Zhong S *et al.* Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. *Br J Cancer* 2004; 90: 1306–11.
- 353 Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. *Ann Rheum Dis* 2006; 65: 983–9.
- 354 Tanaka E, Urata Y. Risk of hepatitis B reactivation in patients treated with tumor necrosis factor-alpha inhibitors. *Hepato Res* 2012; 42: 333–9.
- 355 Iannitto E, Minardi V, Calvaruso G *et al.* Hepatitis B virus reactivation and alemtuzumab therapy. *Eur J Haematol* 2005; 74: 254–8.
- 356 Ritchie D, Piekarczyk RL, Blombery P *et al.* Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report. *Haematologica* 2009; 94: 1618–22.
- 357 Tanaka H, Sakuma I, Hashimoto S *et al.* Hepatitis B reactivation in a multiple myeloma patient with resolved hepatitis B infection during bortezomib therapy: case report. *J Clin Exp Hematop* 2012; 52: 67–9.
- 358 Koike K, Kikuchi Y, Kato M *et al.* Prevalence of hepatitis B virus infection in Japanese patients with HIV. *Hepato Res* 2008; 38: 310–14.
- 359 Nishida K, Yamamoto Y, Kagawa K *et al.* The prevalence of co-infection with hepatitis viruses in human immunodeficiency virus (HIV) infected patients in Japan and the efficacy of hepatitis B virus (HBV)/hepatitis A virus (HAV) vaccination. *J Aids Res* 2007; 9: 30–5. (In Japanese.)
- 360 Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. *J Infect Dis* 1991; 163: 1138–40.
- 361 Koibuchi T, Hitani A, Nakamura T *et al.* Predominance of genotype A HBV in an HBV-HIV-1 dually positive population compared with an HIV-1-negative counterpart in Japan. *J Med Virol* 2001; 64: 435–40.
- 362 Nunez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. *J Hepato Int* 2006; 44: S132–9.
- 363 de Vries-Sluijs TE, Reijnders JG, Hansen BE *et al.* Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. *Gastroenterology* 2010; 139: 1934–41.
- 364 Wever K, van Aghmael MA, Carr A. Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men. *J Acquir Immune Defic Syndr* 2010; 55: 78–81.
- 365 Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 2012. Developed by the HHS Panel on Antiretroviral Guidelines for Adults and Adolescents – A Working Group of the Office of AIDS Research Advisory Council (OARAC). (<http://aidsinfo.nih.gov/guidelines>) 2013.
- 366 Koibuchi T, Shirosaka T *et al.* Health and Science Research Grant from Ministry of Health, Labour and Welfare. Research on AIDS Control Measures. Guidelines for anti-HIV therapy. HIV Infection and Complications Research Group, 2012. (In Japanese.)

BASIC AND TRANSLATIONAL—LIVER

Leptin Receptor Somatic Mutations Are Frequent in HCV-Infected Cirrhotic Liver and Associated With Hepatocellular Carcinoma

Atsuyuki Ikeda,¹ Takahiro Shimizu,¹ Yuko Matsumoto,¹ Yosuke Fujii,¹ Yuji Eso,¹ Tadashi Inuzuka,¹ Aya Mizuguchi,¹ Kazuharu Shimizu,² Etsuro Hatano,³ Shinji Uemoto,³ Tsutomu Chiba,¹ and Hiroyuki Marusawa¹

Departments of ¹Gastroenterology and Hepatology and ³Surgery, Graduate School of Medicine, and ²Department of Nanobio Drug Discovery, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan

See Covering the Cover synopsis on page 2.

BACKGROUND & AIMS: Hepatocellular carcinoma develops in patients with chronic hepatitis or cirrhosis via a stepwise accumulation of various genetic alterations. To explore the genetic basis of development of hepatocellular carcinoma in hepatitis C virus (HCV)-associated chronic liver disease, we evaluated genetic variants that accumulate in nontumor cirrhotic liver. **METHODS:** We determined the whole exome sequences of 7 tumors and background cirrhotic liver tissues from 4 patients with HCV infection. We then performed additional sequencing of selected exomes of mutated genes, identified by whole exome sequencing, and of representative tumor-related genes on samples from 22 cirrhotic livers with HCV infection. We performed *in vitro* and *in vivo* functional studies for one of the mutated genes. **RESULTS:** Whole exome sequencing showed that somatic mutations accumulated in various genes in HCV-infected cirrhotic liver tissues. Among the identified genes, the leptin receptor gene (*LEPR*) was one of the most frequently mutated in tumor and nontumor cirrhotic liver tissue. Selected exome sequencing analyses detected *LEPR* mutations in 12 of 22 (54.5%) nontumorous cirrhotic livers. *In vitro*, 4 of 7 (57.1%) *LEPR* mutations found in cirrhotic livers reduced phosphorylation of STAT3 to inactivate *LEPR*-mediated signaling. Moreover, 40% of *Lepr*-deficient (C57BL/*KsJ*-*db/db*) mice developed liver tumors after administration of thioacetamide compared with none of the control mice. **CONCLUSIONS:** Based on analysis of liver tissue samples from patients, somatic mutations accumulate in *LEPR* in cirrhotic liver with chronic HCV infection. These mutations could disrupt *LEPR* signaling and increase susceptibility to hepatocarcinogenesis.

Keywords: Liver Cancer; Whole Exome Sequencing; Genetics; STAT3.

Chronic inflammation plays an important role in the development of various human cancers. Indeed, many human cancers are closely associated with chronic inflammation, such as *Helicobacter pylori*-associated gastric cancer and inflammatory bowel disease-associated colorectal cancer.^{1,2} On the other hand, tumor cells are

believed to be generated by a stepwise accumulation of genetic alterations in various tumor-related genes during the process of inflammation-associated carcinogenesis.^{3–6} Thus, it is reasonable to assume that somatic mutations latently accumulate in inflamed tissues, where the risk of tumorigenesis is high. Consistent with this hypothesis, several studies have shown frequent somatic mutations in nontumorous inflammatory tissues.^{7,8} To clarify the mechanisms of inflammation-associated carcinogenesis, it is important to unveil the genetic alterations that occur in the inflamed tissues before tumor development. The diversity of mutated genes and the low frequency of genetic alterations compared with tumor tissues, however, are obstacles to revealing the landscape of accumulated genetic aberrations in chronically inflamed nontumorous tissues.

Several possible molecular mechanisms have been proposed for the genetic alterations occurring in the inflammatory condition.⁹ We recently showed that the expression of activation-induced cytidine deaminase (AID), a DNA/RNA mutator enzyme family member, links inflammation to an enhanced susceptibility to genetic aberration during the development of various gastrointestinal and hepatobiliary cancers.^{10–12} One clear example of inflammation-associated cancer is human hepatocellular carcinoma (HCC). HCC arises in the background of chronic inflammation caused by hepatitis C virus (HCV) infection.¹³ We showed that aberrant AID expression triggered by HCV infection and the resultant inflammatory response leads to the generation of somatic mutations in various tumor-related genes in the inflamed liver tissues.^{14,15} The target genes of AID-mediated mutagenesis in the inflamed hepatocytes, however, remain unclear.

Recent advances in sequencing technology have enabled us to reveal the whole picture of human genome sequences in association with the risk of development of a variety of human diseases, including cancers.^{16,17} Whole exome capture

Abbreviations used in this paper: AID, activation-induced cytidine deaminase; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; Ig, immunoglobulin; TAA, thioacetamide.

© 2014 by the AGA Institute
0016-5085/\$36.00

<http://dx.doi.org/10.1053/j.gastro.2013.09.025>

has identified several candidate driver genes in various human cancers.^{18–20} Although deep sequencing on tumor tissues provides the most comprehensive analysis of the cancer genome, the genetic alterations accumulated in chronically inflamed tissues might provide an additional opportunity to clarify the early genetic changes required for carcinogenesis. In the present study, we applied whole exome sequencing to not only the tumor but also nontumorous liver tissues infected with HCV and found that somatic mutations of the leptin receptor gene (*LEPR*) latently underlie a subset of the cirrhotic liver tissues, providing the putative genetic basis for HCV-associated hepatocarcinogenesis.

Materials and Methods

Whole Exome Capture and Massively Parallel Sequencing

Massively parallel sequencing was performed as described previously.^{21,22} Fragmented DNA (more than 5 μ g) was used to prepare each DNA sequencing library. The DNA libraries were prepared according to the instructions provided with the Illumina Preparation Kit (Illumina, San Diego, CA). Whole exome sequence capture was then performed using SeqCap EZ Human Exome Library v2.0 (Roche, Madison, WI) according to the manufacturer's instructions. Cluster generation was performed on the Illumina cluster station (using their TruSeq PE Cluster Kit v5). Paired-end sequence for 2×76 base pairs was performed on the Illumina Genome Analyzer Iix (using their SBS Kits v5). Data collection and base calling were performed using SCS v2.9/RTA 1.9, and the resultant data files were converted to the FASTQ format.

Selected Exome Capture and Massively Parallel Sequencing

Fragmented DNA (1 μ g) was used to prepare each DNA sequencing library. The DNA libraries were prepared using TruSeq DNA Sample Prep Kits (Illumina) according to the manufacturer's protocol. Selected gene capture (*TP53*, *CTNNB1*, *LEPR*) was performed using the SeqCap EZ Choice library (Roche) according to the manufacturer's recommendations. Cluster generation and multiplexed paired-end sequencing for $2 \times 71 + 7$ base pairs was performed as described previously. Data collection and base calling were performed as described previously and demultiplexed using CASAVA version 1.8.2 software (Illumina) with the default settings.

Sequence data analysis and variant filtering, patients, cell culture and transfection, immunoblotting analysis, and animal experiments are described in [Supplementary Methods](#) and [Supplementary Figures 1 and 2](#).

Results

Whole Exome Sequencing Identified the Mutation Signature of Synchronous HCCs in Patients With Chronic HCV Infection

To explore the genetic basis of HCV-associated hepatocarcinogenesis, we first determined the whole exome sequences in matched pairs of HCC and background liver tissues obtained from 4 patients with chronic HCV infection

([Supplementary Table 1](#), patients 1–4). Three of these patients had multiple HCCs, and one had a solitary HCC in the liver. To compare the mutation signature in synchronous HCCs that developed in the same background liver, we determined the whole exome sequences of 2 representative HCCs in 3 cases and a solitary HCC in the remaining case ([Figure 1](#)). These 7 HCCs from 4 patients comprised 2 well-differentiated and 5 moderately differentiated HCCs, and the background liver tissue showed the histological characteristics of cirrhosis. To subtract the normal variants of each individual from the somatic mutations, we also determined the whole exome sequences of matched peripheral lymphocytes in each patient.

On average, we generated approximately 3.1 gigabases of sequence per sample, 80.1% of which were aligned with the human reference genome (Human Genome Build 37.3), and the mean coverage in the targeted regions was 33.8-fold ([Supplementary Table 2](#)). The variant filtering process is summarized in [Supplementary Figure 1](#), and the overall error rate in our current platform was confirmed to be less than 0.2%, as described previously.²¹ Overall, a total of 970 nucleotide positions in 768 different genes were mutated at a frequency of more than 20% of reads in the 7 HCC tissues ([Supplementary Table 3](#)). Among them, 79 genes were recurrently mutated in 2 or more tumor tissues (data not shown). These genes included representative tumor-related genes associated with HCC such as *TP53* (mutated in 2 of 7 tumors). Pathway analyses using Kyoto Encyclopedia of Genes and Genomes (KEGG; <http://www.genome.jp/kegg/>) revealed that metabolic pathway-related genes were most frequently damaged in HCC tissues (5 of 7 tumors) ([Supplementary Table 4](#)).

Interestingly, the mutation signature was remarkably different between the synchronously developed HCCs in each patient ([Figure 1](#)). In patient 3, none of the genes were commonly mutated in the 2 tumors examined, while 29 and 225 genes acquired independent somatic mutations in each tumor, respectively. In contrast, 32 genes (64.0% of mutated genes of HCC 1 in patient 1) and 9 (24.3% of mutated genes of HCC 1 in patient 2) were commonly mutated in the synchronously developed HCCs of those patients, indicating that the synchronous HCCs that developed in patient 1 or 2 shared a common pattern of genetic aberrations. These findings may suggest that the synchronous tumors in patients 1 and 2 were derived from common tumor-precursor cells or developed through intrahepatic metastasis, whereas the tumors in patient 3 developed independently in a multicentric manner.

Somatic Mutations Accumulated in the Cirrhotic Liver With HCV Infection

Whole exome sequencing also revealed a large number of nucleotide alterations in nontumorous cirrhotic liver tissues. In some cases, the total number of mutated genes in nontumorous liver was higher than that in tumor tissues, while the mutation frequency in nontumorous tissues tended to be lower than that in the matched tumor tissues ([Figure 2](#)). Sorting Intolerant From Tolerant (SIFT) functional impact predictions (<http://provean.jcvi.org/index.php>) revealed that the mean percentage of somatic




Figure 1. Schematic diagram showing the number of mutated genes in tumors and the number of genes commonly mutated in both tumor and the matched nontumorous liver tissues. Patients 1, 2, and 3 had synchronously developed HCCs, and patient 4 had a solitary HCC. Venn diagrams represent the number of mutated genes in each HCC tissue determined by whole exome sequencing. The numbers of genes commonly mutated in the synchronously developed multiple HCCs were 32, 9, and 0 in patients 1, 2, and 3, respectively. Among the mutated genes in HCC (at a frequency of more than 20% of reads), the number of genes commonly mutated in both HCC and matched nontumorous background liver (at a frequency of more than 5% of reads) is shown in shaded circles.

mutations predicted to be “damaging” in tumorous and nontumorous tissues was 20.4% and 13.1%, respectively, suggesting that somatic mutations that accumulated in nontumorous tissues included “passenger” mutations with less functional significance more frequently than those that accumulated in tumor tissues (Supplementary Table 3). We also identified a total of 448 indels in 7 HCC tissues (Supplementary Table 5), while fewer indels were detected in all of the nontumorous cirrhotic liver tissues examined (Supplementary Table 6). Consistent with previous studies,¹⁹ we found that one-third of the mutations that accumulated in the exome sequences of HCC tissues were enriched as C>T; G>A transition, followed by A>G; T>C.

Similar to tumor tissues, C>T; G>A transition mutations were most frequently detected in nontumorous cirrhotic tissues (Supplementary Figure 3).

The aim of this study was to identify the somatic mutations in the nontumorous HCV-positive cirrhotic liver that may contribute to tumorigenesis. Therefore, we focused on the genes commonly mutated in both tumor and nontumorous liver tissues from the same patient. Because few genes commonly acquired somatic mutations with a frequency of more than 20% both in the tumor and the matched nontumorous liver tissues, we selected potential somatic mutations in nontumorous tissues that represented more than 5% of the total reads for further evaluation




Figure 2. The number of mutated genes and the distribution of mutation frequency in tumor and nontumorous cirrhotic liver tissues. The number of mutated genes (*upper panel*) and the distribution of mutation frequency (*lower panel*) detected by whole exome sequencing in each sample are shown (at a frequency of more than 20% of reads). Patients 1, 2, and 4 had more mutated genes in nontumorous liver tissue than those in HCC, while the mutation frequency at each nucleotide position in the majority of nontumorous cirrhotic liver tissues was <30%. NT, nontumorous cirrhotic liver.

(Supplementary Figure 1). The 5% threshold in nontumorous liver was chosen because common polymorphisms in each patient were excluded by determining the nucleotide changes with a frequency of more than 5% in the matched normal samples, such as peripheral lymphocytes.^{18,23}

Based on these criteria, nucleotide positions that were commonly mutated in both the tumor (at a frequency of more than 20% of reads) and the matched background liver (at a frequency of more than 5% of reads) of each patient were detected (Figure 1). Among them, we focused on 40 mutations that result in amino acid changes (Supplementary Table 7) and found that only 2 genes, *LEPR* and *ZNF408*, were recurrently mutated with a frequency greater than 5% of reads in nontumorous cirrhotic livers from 2 of the 4 patients (listed as the top 2 genes in Supplementary Table 7). Of these 2 genes, we focused on *LEPR*, which has mutations that have been correlated with various human diseases, such as obesity and metabolic disorders.²⁴

Identification of *LEPR* as the Recurrently Mutated Gene in Cirrhotic Livers With HCV Infection

We designed a selected sequence capture system that enabled us to enrich the whole exonic sequences of the

LEPR followed by deep sequencing. In addition, selected exonic capture of *TP53* and *CTNNB1*, the representative driver genes for hepatocarcinogenesis,^{19,20,25} was performed on the same cohort. Accordingly, the selected exonic sequencing was applied to 22 additional HCV-positive cirrhotic liver tissues, 10 HCC tissues, and matched peripheral lymphocytes from 22 patients (Supplementary Table 1, patients 5–26). Selected exome sequencing generated a mean coverage of 996-, 1656-, and 2348-fold on *LEPR*, *TP53*, and *CTNNB1*, respectively (Supplementary Table 8). The variant filtering process is summarized in Supplementary Figure 2, and we detected both high-frequency (at a frequency of more than 20% of reads) and low-frequency (at a frequency of 1%–20% of reads) mutations separately.

High-frequency mutations in *TP53* and *CTNNB1* were detectable in 1 of 10 (10%) and 1 of 10 (10%) of the HCCs, respectively (Table 1), and these rates in the HCCs were consistent with recent deep-sequencing studies.^{19,20} None of the nontumorous liver tissues possessed high-frequency mutations in *TP53* or *CTNNB1*; however, low-frequency mutations of *TP53* and *CTNNB1* were detected in 17 of 22 (77.3%) and 12 of 22 (54.5%) of the nontumorous livers, respectively. These findings indicated that somatic mutations in the representative cancer driver genes latently

Table 1. Number of Tumor Tissues and Nontumorous Cirrhotic Liver Tissues With Somatic Mutations at High and Low Frequencies in *TP53*, *CTNNB1*, and *LEPR*

	<i>LEPR</i>	<i>TP53</i>	<i>CTNNB1</i>
High-frequency mutations (>20%)			
Tumor (n = 10)	0	1	1
Nontumor (n = 22)	1 ^a	0	0
Low-frequency mutations (1%–20%)			
Tumor (n = 10)	9	8	9
Nontumor (n = 22)	12 ^a	17	12

^aOne patient had both high-frequency and low-frequency mutations in *LEPR*.

accumulated with a relatively low frequency in the cirrhotic livers with HCV infection.

Interestingly, we also found high- and/or low-frequency mutations in *LEPR* in both tumor and nontumorous liver tissues. Indeed, 9 of 10 (90%) tumors and 12 of 22 (54.5%) nontumorous cirrhotic livers possessed high- and/or low-frequency mutations in *LEPR* (Table 1). Notably, some somatic mutations were commonly detected in different positions of the same patient's liver. For example, C1084T (reference position: 65557165) mutations of *LEPR* were detected in the right, left, and caudate lobes of one patient (Supplementary Table 1, patient 11), suggesting that some of the hot spots of the acquired somatic mutations in the *LEPR* gene are commonly present in hepatocytes of the same liver underlying HCV infection. On the other hand, no mutations in *LEPR* were identified by deep sequencing analysis of noncirrhotic liver tissues from patients with chronic HCV infection or liver tissue from patients without HCV infection. (Supplementary Table 9). To confirm the somatic mutations present in *LEPR* in the nontumorous liver, we validated the candidate mutations by Sanger sequencing. For this purpose, we determined the sequences of exons 9 and 10 of *LEPR* of at least 50 randomly picked clones that were amplified from the nontumorous liver tissues of each patient. Although it was difficult to detect all the low-frequency mutations using the conventional cloning-sequencing method, we confirmed that somatic mutations were recurrently accumulated in *LEPR* of nontumorous cirrhotic liver tissues (Supplementary Figure 4).

LEPR Mutations Found in HCV-Positive Cirrhotic Liver Resulted in the Disruption of Downstream Signaling

Selected exome sequencing detected low-frequency mutations at a total of 650 nucleotide positions of *LEPR* in 12 of 22 (54.5%) HCV-positive cirrhotic liver tissues. Although the nucleotide changes were unevenly distributed throughout the whole *LEPR* exonic sequences, we detected 67 nucleotide alterations at the immunoglobulin (Ig) domain of *LEPR*, 38 of which (56.7%) were recurrently

mutated in 2 or more patients (Figure 3A). Among them, nonsynonymous mutations that caused the amino acid changes were detected at 62 of the 67 (92.5%) nucleotide positions, and 10 of the 62 were also mutated in at least one HCC tissue examined in this study. Histological examination revealed no significant association between the presence of *LEPR* mutations and the level of fatty changes in the liver tissue (data not shown).

To explore the functional relevance of *LEPR* mutations detected in HCV-positive cirrhotic liver tissues, we randomly selected 7 *LEPR*s with a mutated Ig domain from 62 nonsynonymously mutated *LEPR*s and examined the downstream signaling properties of the mutated *LEPR* in vitro.

Accordingly, we subcloned the mutated *LEPR*s and constructed expression plasmids encoding those mutant *LEPR*s (Figure 3B). We first confirmed that only a small amount of endogenous *LEPR* expression was observed in both HEK293 and HepG2 cells (Supplementary Figure 5) and the induction of the phosphorylation of STAT3 by wild-type *LEPR* in the presence of recombinant human leptin (Figure 3C). In contrast, 4 of 7 (57.1%) mutations in the Ig domain of *LEPR* resulted in the reduction or loss of STAT3 phosphorylation in vitro (Figure 3C). To clarify the functional significance of *LEPR* mutations, the cell proliferation rate was determined in HepG2 cells expressing either wild-type or mutated *LEPR*s that were identified in HCV-positive cirrhotic liver tissues using the lentivirus system.²⁶ Up-regulation of cyclin D1 and/or E transcripts as well as enhanced cell proliferation were observed in the cells with expression of the mutated *LEPR* gene compared with wild-type cells, while there was no difference in the expression levels and subcellular localization between wild-type and mutated *LEPR* protein (Supplementary Figure 6). These findings indicate that some of the somatic mutations that latently accumulated in the Ig domain of *LEPR* of the cirrhotic liver tissue might cause dysfunction of *LEPR*-mediated signaling in the cells with those somatic mutations.

LEPR Dysfunction Enhanced Susceptibility to Tumorigenesis

To determine the functional relevance of *LEPR* dysfunction on development of liver cancer, we examined whether disruption of the *LEPR* gene contributes to liver tumorigenesis using a genetically altered mouse model, the *Lepr*-deficient C57BL/KsJ-*db/db* mouse (hereafter referred to as *db/db* mouse).²⁷ Thioacetamide (TAA), a putative carcinogen, is well established to induce liver fibrosis and tumorigenesis in a murine model.²⁸ Thus, we conducted an assay to evaluate whether *LEPR* insufficiency alters the effects of TAA-mediated tumorigenesis. Accordingly, TAA was prepared at a concentration of 0.02%, a relatively low dose compared with the carcinogenic dose,²⁹ and administered in drinking water to mice for 24 weeks. The body weight of the *db/db* mice was about twice that of their lean littermates, and *db/db* mice had hepatomegaly even after normalizing the liver weight to the body weight (Figure 4A). Histological